APOE and chronic kidney disease: The lifespan of CKD patients is shortened; cardiovascular diseases (CVD) account for premature death in more than 50% of patients with CKD.[1] Atherosclerosis (AS) is the leading cause of cardiovascular morbidity and mortality in patients with CKD, and its progression is often accelerated.[2, 3, 4] Notably, thrombotic events are more likely to occur in patients with CKD, as well as in apolipoprotein E‐deficient (ApoE−/−) mice with CKD (CKD/ApoE−/− mice),[4] hinting that the plaques in CKD may exhibit some characters of vulnerability and be susceptible to rupture.